SEONGNAM, South Korea, Aug. 5, 2024 /PRNewswire/ — SK pharmteco, a global contract development, manufacturing, and analytical testing organization serving both the small molecule and cell & gene therapy industry, and Rznomics Inc., a South Korea-based biopharmaceutical company specializing in the development of RNA-based gene therapeutics, have signed a memorandum of understanding (MOU) for a contract development and manufacturing partnership.
When finalized, the multi-year partnership will establish a strategic collaboration between SK pharmteco and Rznomics to develop and commercialize multiple gene therapy products. SK pharmteco will provide technical expertise and resources, including the facilities and personnel, to enable a smooth transition from clinical to full-scale commercial manufacturing of Rznomics’ innovative ribonucleic acid (RNA)-based biopharmaceuticals.
“We are thrilled about the opportunity to partner with Rznomics on their groundbreaking initiatives,” said Andy Fenny, Chief Commercial Officer of SK pharmteco. “By combining our significant expertise in gene therapy manufacturing with Rznomics’ innovative RNA-based therapeutic approach, we believe this collaboration has the potential to deliver life-changing treatments to patients in need quickly.”
Seong-Wook Lee, President and Chief Executive Officer of Rznomics, commented: “This partnership will mark late-stage development and manufacturing of our gene therapy pipeline to prepare the path towards Phase II and later stage clinical trials and potential commercialization. We look forward to working closely with SK pharmteco.”
About SK pharmteco
SK pharmteco is a global contract development and manufacturing organization (CDMO) with 13 offices and manufacturing facilities across the U.S., Europe, and Korea. The company partners with biopharmaceutical companies of all sizes to manufacture Active Pharmaceutical Ingredients (API) and intermediates, cell and gene therapy technologies, registered starting materials, and analytical services for the biopharmaceutical industry worldwide. SK pharmteco is a subsidiary of SK Inc. (KRX: 034730) (SK), the strategic investment company for SK Group, South Korea’s second-largest conglomerate.
About Rznomics
Rznomics is a South Korea-based innovative RNA biopharmaceutical company, with vision to treat/conquer various human intractable diseases.
Rznomics has developed and focused on several pipelines with RNA editing platform technologies of RZ-001 (Hepatocellular Carcinoma, Glioblastoma), RZ-003 (Alzheimer), RZ-004 (Retinitis Pigmentosa), RZ-005 (neurodegenerative disorder) and Circular RNA platform.
For RZ-001, the lead pipeline, Rznomics has received Phase I/IIa IND approvals from the FDA for Hepatocellular Carcinoma and Glioblastoma in 2022 and 2023 each. In addition, FDA has granted Fast Track Designation for GBM in November 2023 and Orphan Drug Designation for HCC in January 2024.
Early-phase trials have also commenced in Korea, upon IND approval for RZ-001 from the Ministry of Food and Drug Safety (MFDS). Rznomics has received IND approval for combination of RZ-001 and Immunotherapy from the MFDS as well, in December 2023.
https://www.prnewswire.com/news-releases/sk-pharmteco-and-rznomics-explore-collaboration-for-rna-based-gene-therapy-development-and-manufacturing-302213313.html

Check out our AAV CDMO service to expedite your gene therapy research
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Navega Therapeutics Receives $4 Million CIRM Grant to Advance Epigenetic Gene Therapy for Chronic Pain
SAN DIEGO, CA – February 4, 2025 – Navega Therapeutics, a pioneering biotechnology company developing cutting-edge epigenetic gene therapies, today announced a significant milestone with the receipt of a $4 million Translational Science grant from the California...
Akribion Therapeutics Secures €8 Million in Seed Financing to Advance Novel RNA-Guided Cell Depletion Technology
ZWINGENBERG, Germany, February 4, 2025 – Akribion Therapeutics, a biotechnology company pioneering a unique, RNA-guided, nuclease-based technology for programmable cell depletion, today announced the closing of an €8 million Seed financing round. The round was led by...
UF-Kure19 CAR-T Cell Therapy Demonstrates High CR Rates, Low Toxicity in R/R NHL
Treatment with UF-Kure19, a rapidly manufactured CAR T-cell therapy, led to complete responses (CR) and low toxicity in patients with relapsed/refractory non-Hodgkin lymphoma, according to data from a single-arm, mult-center phase 1 study (NCT05400109) presented at...
Opinion: Companies Vie to Develop a Hunter Syndrome Therapy That Reaches the Brain
Several companies—including JCR Pharmaceuticals, Denali Therapeutics and Regenxbio—have products in the pipeline that could improve treatment options for this rare disease. Hunter syndrome is a rare, X‐linked disease caused by a deficiency of the lysosomal enzyme...
Related Services

Plasmids GMP Services

AAV GMP Services
